OTX 015

Drug Profile

OTX 015

Alternative Names: MK 8628; OTX-015; Y-803

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Merck & Co; Mitsubishi Tanabe Pharma Corporation; OncoEthix
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Small molecules; Triazoles
  • Mechanism of Action BRD2-protein-inhibitors; BRD3 protein inhibitors; BRD4-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • Phase I Haematological malignancies
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 28 Dec 2016 OTX 015 is still in phase I trials for Haematological malignancies in France, Italy and Switzerland
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Haematological malignancies presented at 58th Annual Meeting and Exposition of the American Society of Hematology
  • 29 Nov 2016 Efficacy, pharmacokinetics and adverse events data from a phase Ib trial in Solid tumours data presented at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top